Skip to main content

Resmed Inc

RSMDF
Exchange
OTC
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0000943819

In the last 90 days, Resmed Inc insiders filed 0 open-market purchases and 5 sales; 1 institution reported holding it in 13F filings for Q2 2026, worth $1.17K in total; no superinvestor holds it.

Other share classesRMD

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Resmed Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
5 filings
2 insiders, $5.26M in total
Insiders trading
2
Net value
−$5.26M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Resmed Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Resmed Inc
NameTitleLast reported holdingLast filingFilings, past year
Farrell Michael J.Chairman and CEO466,256Sep 10, 202615
Farrell Peter CDirector51,803Sep 4, 202611
Rider Michael JGlobal General Counsel9,488Jun 3, 20266
Sandercock BrettChief Financial Officer83,495May 4, 20269
De Witte JanDirector4,261Nov 26, 20253
Mowad-Nassar NicoleDirector777Nov 26, 20252
Taylor Ronald RDirector24,771Nov 24, 20251
Burt CarolDirector2,156Nov 24, 20251
Drexler KarenDirector10,602Nov 24, 20251
Gill HarjitDirector10,940Nov 24, 20252
Leong JustinChief Product Officer29,028Nov 24, 20251
DelOrefice ChristopherDirector2,423Nov 24, 20251
Tan DesneyDirector6,002Nov 24, 20251
Hernandez JohnDirector5,118Nov 24, 20251
Sulpizio RichardDirector17,796Nov 21, 20251
Ghoshal KaushikChief Commercial Officer, SaaS9,725Aug 5, 20250
Douglas Robert AndrewSpecial Advisor13,849Jan 3, 20240
Blaise LucilePresident, Sleep & RC Business10,305Nov 16, 20230
Pendarvis DavidChief Administrative Officer89,729Jun 30, 20230
Hollingshead JamesPresident, Sleep Business76,721Dec 1, 20210
Resmed IncDirector13,823Nov 22, 20210
Sodhi RajwantPresident, SaaS Business26,731Oct 14, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 4, 2024 (view filing)Mar 13 daysRider Michael JGlobal General CounselSSaleResMed Common Stock−200$173.25−$34.6K−2.9%6.69K after10b5-1
Feb 23, 2024 (view filing)May 3, 2023-Feb 22, 2024296 daysLateFarrell Peter CDirectorSSaleResMed Common Stock−23.5K$211.84−$4.99M−13.0%157.4K after2 lots
Nov 29, 2023 (view filing)Nov 272 daysSandercock BrettChief Financial OfficerSSaleResMed Common Stock−3.00K$152.62−$457.9K−3.1%93.0K after
Nov 16, 2023 (view filing)Nov 151 dayFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−5.68K$152.04−$863.3K−1.3%441.0K after10b5-1
Nov 2, 2023 (view filing)Nov 11 dayRider Michael JGlobal General CounselSSaleResMed Common Stock−25$143.42−$3.59K−0.3%7.36K after10b5-1
Oct 17, 2023 (view filing)Oct 161 dayFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−5.67K$140.70−$798.5K−1.2%449.4K after10b5-1
Oct 4, 2023 (view filing)Oct 22 daysRider Michael JGlobal General CounselSSaleResMed Common Stock−25$145.92−$3.65K−0.3%7.38K after10b5-1
Sep 19, 2023 (view filing)Sep 154 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−5.67K$146.35−$830.5K−1.2%449.4K after10b5-1
Sep 7, 2023 (view filing)Sep 16 daysLateRider Michael JGlobal General CounselSSaleResMed Common Stock−25$161.15−$4.03K−0.3%7.41K after10b5-1
Aug 17, 2023 (view filing)Aug 152 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−5.67K$183.20−$1.04M−1.3%436.9K after10b5-1
Aug 16, 2023 (view filing)Aug 151 dayDouglas Robert AndrewPresident and COOSSaleResMed Common Stock−1.50K$181.01−$271.5K−0.6%250.5K after10b5-1
Aug 2, 2023 (view filing)Aug 11 dayRider Michael JGlobal General CounselSSaleResMed Common Stock−25$224.12−$5.60K−0.5%5.19K after10b5-1
Jul 19, 2023 (view filing)Jul 172 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−5.67K$221.27−$1.26M−1.3%436.9K after10b5-1
Jul 18, 2023 (view filing)Jul 171 dayDouglas Robert AndrewPresident and COOSSaleResMed Common Stock−1.50K$222.22−$333.3K−0.6%252.0K after10b5-1
Jul 14, 2023 (view filing)Jul 131 dayGhoshal KaushikPresident, SaaS BusinessSSaleResMed Common Stock−500$220.00−$110.0K−4.1%11.8K after10b5-1
Jul 5, 2023 (view filing)Jul 32 daysRider Michael JGlobal General CounselSSaleResMed Common Stock−25$217.21−$5.43K−0.5%5.21K after10b5-1
Jun 20, 2023 (view filing)Jun 155 daysDouglas Robert AndrewPresident and COOSSaleResMed Common Stock−1.50K$216.27−$324.4K−0.6%253.5K after10b5-1
Jun 16, 2023 (view filing)Jun 151 dayFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−5.67K$217.39−$1.23M−1.3%436.9K after10b5-1
Jun 7, 2023 (view filing)Jun 52 daysPendarvis DavidChief Administrative OfficerSSaleResMed Common Stock−1.50K$219.79−$329.7K−1.6%89.7K after10b5-1
Jun 6, 2023 (view filing)Jun 24 daysGhoshal KaushikPresident, SaaS BusinessSSaleResMed Common Stock−500$220.00−$110.0K−3.9%12.3K after10b5-1
May 17, 2023 (view filing)May 152 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−5.67K$232.10−$1.32M−1.3%436.9K after10b5-1
May 16, 2023 (view filing)May 151 dayDouglas Robert AndrewPresident and COOSSaleResMed Common Stock−1.50K$232.85−$349.3K−0.6%255.0K after10b5-1
May 12, 2023 (view filing)May 102 daysSandercock BrettChief Financial OfficerSSaleResMed Common Stock−12.6K$233.13−$2.93M−12.1%90.9K after
May 10, 2023 (view filing)May 91 daySandercock BrettChief Financial OfficerSSaleResMed Common Stock−3.43K$232.05−$795.0K−3.2%103.5K after
May 4, 2023 (view filing)May 31 dayPendarvis DavidChief Administrative OfficerSSaleResMed Common Stock−1.50K$237.64−$356.5K−1.6%91.2K after10b5-1
May 2, 2023 (view filing)May 11 dayGhoshal KaushikPresident, SaaS BusinessSSaleResMed Common Stock−500$239.30−$119.7K−3.8%12.7K after10b5-1
Apr 25, 2023 (view filing)Apr 241 dayGhoshal KaushikPresident, SaaS BusinessSSaleResMed Common Stock−2.00K$230.00−$460.0K−13.2%13.2K after
Apr 18, 2023 (view filing)Apr 171 dayDouglas Robert AndrewPresident and COOSSaleResMed Common Stock−1.50K$224.65−$337.0K−0.6%256.5K after10b5-1
Apr 18, 2023 (view filing)Apr 171 dayFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−5.67K$224.23−$1.27M−1.3%436.9K after10b5-1
Apr 5, 2023 (view filing)Apr 32 daysPendarvis DavidChief Administrative OfficerSSaleResMed Common Stock−1.50K$218.23−$327.3K−1.6%92.7K after
Apr 5, 2023 (view filing)Apr 32 daysGhoshal KaushikPresident, SaaS BusinessSSaleResMed Common Stock−500$220.00−$110.0K−3.2%15.2K after
Mar 17, 2023 (view filing)Mar 152 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−5.67K$206.95−$1.17M−1.3%436.9K after
Mar 16, 2023 (view filing)Mar 151 dayDouglas Robert AndrewPresident and COOSSaleResMed Common Stock−1.50K$206.14−$309.2K−0.6%258.0K after
Mar 7, 2023 (view filing)Mar 34 daysPendarvis DavidChief Administrative OfficerSSaleResMed Common Stock−1.50K$216.69−$325.0K−1.6%94.2K after
Mar 7, 2023 (view filing)Mar 34 daysGhoshal KaushikPresident, SaaS BusinessSSaleResMed Common Stock−1.00K$220.00−$220.0K−6.0%15.7K after
Feb 22, 2023 (view filing)Feb 175 daysSandercock BrettChief Financial OfficerSSaleResMed Common Stock−10.0K$215.22−$2.15M−8.6%106.9K after
Feb 16, 2023 (view filing)Feb 151 dayDouglas Robert AndrewPresident and COOSSaleResMed Common Stock−1.50K$213.50−$320.3K−0.6%261.4K after
Feb 16, 2023 (view filing)Feb 151 dayFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−5.67K$214.83−$1.22M−1.3%436.9K after
Feb 14, 2023 (view filing)Feb 131 daySandercock BrettChief Financial OfficerSSaleResMed Common Stock−4.00K$215.00−$860.0K−3.3%116.9K after
Feb 6, 2023 (view filing)Feb 33 daysPendarvis DavidChief Administrative OfficerSSaleResMed Common Stock−1.50K$224.50−$336.8K−1.5%95.7K after
Feb 3, 2023 (view filing)Feb 21 dayDrexler KarenDirectorSSaleResMed Common Stock−594$226.58−$134.6K−6.9%7.99K after
Jan 18, 2023 (view filing)Jan 171 dayDouglas Robert AndrewPresident and COOSSaleResMed Common Stock−1.50K$220.43−$330.6K−0.7%226.2K after
Jan 18, 2023 (view filing)Jan 171 dayFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−5.67K$224.36−$1.27M−1.3%436.9K after
Jan 5, 2023 (view filing)Jan 32 daysPendarvis DavidChief Administrative OfficerSSaleResMed Common Stock−1.50K$210.07−$315.1K−1.5%97.2K after
Dec 16, 2022 (view filing)Dec 151 dayFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−5.67K$215.63−$1.22M−1.3%436.9K after
Dec 6, 2022 (view filing)Dec 51 dayPendarvis DavidChief Administrative OfficerSSaleResMed Common Stock−1.50K$229.81−$344.7K−1.5%98.7K after
Nov 23, 2022 (view filing)Nov 221 dayLeong JustinPresident, Asia Latin AmericaSSaleReMed Common Stock−3.78K$229.50−$866.8K−5.9%59.8K after
Nov 16, 2022 (view filing)Nov 151 dayFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−5.67K$224.64−$1.27M−1.4%414.0K after
Nov 16, 2022 (view filing)Nov 151 dayDouglas Robert AndrewPresident and COOSSaleResMed Common Stock−11.3K$222.07−$2.50M−21.9%40.2K after
Nov 14, 2022 (view filing)Nov 104 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−4.88K$220.83−$1.08M−100.0%0 after